# IL-15 Superagonist With or Without Vaccine in Biochemically Recurrent Prostate Cancer After Previous Stereotactic Body Radiation Therapy

> **NCT07686380** · PHASE2 · RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 65 (estimated)

## Conditions studied

- Recurrent Prostate Cancer
- Prostate Cancer

## Interventions

- **DRUG:** N-803
- **DRUG:** ETBX-71 Vaccine
- **RADIATION:** 18F-DCFPyL

## Key facts

- **NCT ID:** NCT07686380
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-10-01
- **Primary completion:** 2029-01-30
- **Final completion:** 2029-01-30
- **Target enrollment:** 65 (ESTIMATED)
- **Last updated:** 2026-10-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07686380

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07686380, "IL-15 Superagonist With or Without Vaccine in Biochemically Recurrent Prostate Cancer After Previous Stereotactic Body Radiation Therapy". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07686380. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*